Shein-Chung Chow, Jen-Pei Liu

Clinical Trials 3e

• Gebundenes Buch

Produktbeschreibung

Clinical trials are conducted to allow safety and efficacy data to be collected for health interventions. These trials can only take place once satisfactory information has been gathered on the quality of the non-clinical safety. The purpose of this clinical trials book is to provide a comprehensive and unified presentation of designs and analyses utilized at different stages of clinical research and development. It incorporates actual clinical trials in order to feature everyday applicability and explains concepts through illustrations and numerous real examples from clinical trials

---

Praise for the Second Edition:

"...a grand feast for biostatisticians. It stands ready to satisfy the appetite of any pharmaceutical scientist with a respectable statistical appetite." --Journal of Clinical Research Best Practices

The Third Edition of Design and Analysis of Clinical Trials provides complete, comprehensive, and expanded coverage of recent health treatments and interventions. Featuring a unified presentation, the book provides a well-balanced summary of current regulatory requirements and recently developed statistical methods as well as an overview of the various designs and analyses that are utilized at different stages of clinical research and development. Additional features of this Third Edition include:

New chapters on biomarker development and target clinical trials, adaptive design, trials for evaluating diagnostic devices, statistical methods for translational medicine, and traditional Chinese medicine

A balanced overview of current and emerging clinical issues as well as newly developed statistical methodologies

Practical examples of clinical trials that demonstrate everyday applicability, with illustrations and examples to explain key concepts

New sections on bridging studies and global trials, QT studies, multinational trials, comparative effectiveness trials, and the analysis of QT/QTc prolongation

A complete and balanced presentation of clinical and scientific issues, statistical concepts, and methodologies for bridging clinical and statistical disciplines

An update of each chapter that reflects changes in regulatory requirements for the drug review and approval process and recent developments in statistical design and methodology for clinical research and development

Design and Analysis of Clinical Trials, Third Edition continues to be an ideal clinical research reference for academic, pharmaceutical, medical, and regulatory scientists/researchers, statisticians, and graduate-level students.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Wiley Series in Probability and Statistics .
• Verlag: Wiley & Sons
• Artikelnr. des Verlages: 14588765000
• 3. Aufl.
• Seitenzahl: 892
• Erscheinungstermin: 18. November 2013
• Englisch
• Abmessung: 260mm x 183mm x 52mm
• Gewicht: 1844g
• ISBN-13: 9780470887653
• ISBN-10: 0470887656
• Artikelnr.: 36273238

Autorenporträt

SHEIN-CHUNG CHOW, PhD, is Professor in the Department of Biostatistics and Bioinformatics at Duke University School of Medicine. JEN-PEI LIU, PhD, is Professor in the Department of Agronomy and Institute of Epidemiology and Preventive Medicine at the National Taiwan University. He has authored multiple articles and books on clinical trials and been involved in clinical trials as a biostatistician for more than twenty-five years.

Inhaltsangabe

Preface xi
PART I PRELIMINARIES
1 Introduction 3
1.1 What are Clinical Trials?, 3
1.2 History of Clinical Trials, 4
1.3 Regulatory Process and Requirements, 10
1.4 Investigational New Drug Application, 17
1.5 New Drug Application, 24
1.6 Clinical Development and Practice, 31
1.7 AIMS and Structure of the Book, 42
2 Basic Statistical Concepts 45
2.1 Introduction, 45
2.2 Uncertainty and Probability, 46
2.3 Bias and Variability, 49
2.4 Confounding and Interaction, 57
2.5 Descriptive and Inferential Statistics, 66
2.6 Hypotheses Testing and p-Values, 68
2.7 Clinical Significance and Clinical Equivalence, 75
2.8 Reproducibility and Generalizability, 79
3 Basic Design Considerations 85
3.1 Introduction, 85
3.2 Goals of Clinical Trials, 86
3.3 Target Population and Patient Selection, 90
3.4 Selection of Controls, 97
3.5 Statistical Considerations, 105
3.6 Other Issues, 112
3.7 Discussion, 115
4 Randomization and Blinding 117
4.1 Introduction, 117
4.2 Randomization Models, 118
4.3 Randomization Methods, 124
4.4 Implementation of Randomization, 144
4.5 Generalization of Controlled Randomized Trials, 149
4.6 Blinding, 153
4.7 Discussion, 160
PART II DESIGNS AND THEIR CLASSIFICATIONS
5 Designs for Clinical Trials 165
5.1 Introduction, 165
5.2 Parallel Group Designs, 167
5.3 Clustered Randomized Designs, 172
5.4 Crossover Designs, 177
5.5 Titration Designs, 185
5.6 Enrichment Designs, 191
5.7 Group Sequential Designs, 195
5.8 Placebo-Challenging Designs, 197
5.9 Blinded Reader Designs, 203
5.10 Discussion, 207
6 Designs for Cancer Clinical Trials 211
6.1 Introduction, 211
6.2 General Considerations for Phase I Cancer Clinical Trials, 213
6.3 Single-Stage Up-and-Down Phase I Designs, 214
6.4 Two-Stage Up-and-Down Phase I Designs, 217
6.5 Continual Reassessment Method Phase I Designs, 219
6.6 Optimal and Flexible Multiple-Stage Designs, 222
6.7 Randomized Phase II Designs, 229
6.8 Discussion, 232
7 Classification of Clinical Trials 237
7.1 Introduction, 237
7.2 Multicenter Trials, 238
7.3 Superiority Trials, 245
7.4 Active Control and Equivalence/Noninferiority Trials, 248
7.5 Dose-Response Trials, 261
7.6 Combination Trials, 266
7.7 Bridging Studies and Global Trials, 278
7.8 Vaccine Clinical Trials, 285
7.9 QT Studies, 291
7.10 Discussion, 299
PART III ANALYSIS OF CLINICAL DATA
8 Analysis of Continuous Data 305
8.1 Introduction, 305
8.2 Estimation, 306
8.3 Test Statistics, 310
8.4 Analysis of Variance, 316
8.5 Analysis of Covariance, 323
8.6 Nonparametric Methods, 325
8.7 Repeated Measures, 332
8.8 Discussion, 341
9 Analysis of Categorical Data 343
9.1 Introduction, 343
9.2 Statistical Inference for One Sample, 345
9.3 Inference of Independent Samples, 358
9.4 Ordered Categorical Data, 364
9.5 Combining Categorical Data, 368
9.6 Model-Based Methods, 374
9.7 Repeated Categorical Data, 382
9.8 Discussion, 387
10 Censored Data and Interim Analysis 389
10.1 Introduction, 389
10.2 Estimation of the Survival Function, 391
10.3 Comparison Between Survival Functions, 399
10.4 Cox's Proportional Hazard Model, 405
10.5 Calendar Time and Information Time, 419
10.6 Group Sequential Methods, 424
10.7 Discussion, 438
11 Sample Size Determination 441
11.1 Introduction, 441
11.2 Basic Concept, 442
11.3 Two Samples, 447
11.4 Multiple Samples, 456
11.5 Censored Data, 459
11.6 Dose-Response Studies, 464
11.7 Crossover Designs, 471
11.8 Equivalence and Noninferiority Trials, 481
11.9 Multiple-Stage Design in Cancer Trials, 490
11.10 Multinational Trials, 490
11.11 Comparing Variabilities, 500
11.12 Discussion, 517
PART IV ISSUES IN EVALUATION
12 Issues in Efficacy Evaluation 521
12.1 Introduction, 521
12.2 Baseline Comparison, 523
12.3 Intention-to-Treat Principle and Efficacy Analysis, 528
12.4 Adjustment for Covariates, 536
12.5 Multicenter Trials, 541
12.6 Multiplicity, 548
12.7 Data Monitoring, 558
12.8 Use of Genetic Information for Evaluation of Efficacy, 564
12.9 Sample Size Reestimation, 570
12.10 Discussion, 572
13 Safety Assessment 573
13.1 Introduction, 573
13.2 Extent of Exposure, 574
13.3 Coding of Adverse Events, 582
13.4 Analysis of Adverse Events, 595
13.5 Analysis of Laboratory Data, 602
13.6 Analysis of QT/QTc Prolongation, 610
13.7 Discussion, 615
PART V RECENT DEVELOPMENT
14 Biomarkers and Targeted Clinical Trials 619
14.1 Introduction, 619
14.2 Concepts and Strategies, 620
14.3 Biomarker Development and Validation, 623
14.4 Designs of Targeted Clinical Trials, 630
14.5 Analyses of Targeted Clinical Trials, 640
14.6 Discussion, 647
15 Trials for Evaluating Accuracy of Diagnostic Devices 649
15.1 Introduction, 649
15.2 Study Design, 651
15.3 Measures of Diagnostic Accuracy, 656
15.4 Reporting Results, 663
15.5 Sample Size Estimation, 672
15.6 Discussion, 675
16 Statistical Methods in Translational Medicine 677
16.1 Introduction, 677
16.2 Biomarker Development, 678
16.3 Bench-to-Bedside, 682
16.4 Animal Model Versus Human Model, 689
16.5 Translation in Study Endpoints, 691
16.6 Bridging Studies, 696
16.7 Discussion, 699
16.8 Appendix, 700
17 Adaptive Clinical Trial Designs 703
17.1 Introduction, 703
17.2 What Is Adaptive Design?, 704
17.3 Well-Understood and Less Well-Understood Designs, 709
17.4 Clinical/Statistical and Regulatory Perspectives, 713
17.5 Impact of Protocol Amendments, 716
17.6 Challenges in By-Design Adaptations, 721
17.7 Obstacles of Retrospective Adaptations, 727
17.8 Discussion, 729
18 Traditional Chinese Medicine 733
18.1 Introduction, 733
18.2 Fundamental Differences, 734
18.3 Basic Considerations of TCM Clinical Trials, 741
18.4 Other Issues in TCM Research and Development, 744
18.5 Consortium for Globalization of Traditional Chinese Medicine, 751
18.6 Discussion, 752
PART VI CONDUCT OF CLINICAL TRIALS
19 Preparation and Implementation of a Clinical Protocol 755
19.1 Introduction, 755
19.2 Structure and Components of a Protocol, 756
19.3 Points to be Considered and Common Pitfalls During Development
and Preparation of a Protocol, 762
19.4 Common Departures for Implementation of a Protocol, 765
19.5 Monitoring, Audit, and Inspection, 771
19.6 Quality Assessment of a Clinical Trial, 775
19.7 Discussion, 777
20 Data Management of a Clinical Trial 779
20.1 Introduction, 779
20.2 Regulatory Requirements, 781
20.3 Development of Case Report Forms, 783
20.4 Database Development, 787
20.5 Data Entry, Query, and Correction, 788
20.6 Data Validation and Quality, 791
20.7 Database Lock, Archive, and Transfer, 792
20.8 Critical Issues, 795
References 799
Appendix A 845
Index 851

Rezensionen

"In summary, this third edition is an impressive expansion beyond a remarkable second edition. This book would be good reference for biostatisticians, clinical researchers, and pharmaceutical scientists in clinical research and development." (Journal of Biopharmaceutical Statistics, 1 July 2014)